Diabetes is life long affliction that causes a person’s blood sugar level to become too high. With the two main types of diabetes, type 2 is far more common. Around 90% of all adults with diabetes have type 2.
Types
Type 2 is where the body is not creating enough insulin or the body is not reacting correctly to the insulin. This type usually requires the managing of medication, finding the right medication for each person can take time. Also many of the medications have side affects.
Type 1 is when the level of glucose in blood to be too high. This happens when the body isn’t producing enough of the hormone insulin which controls the levels of glucose in blood.
Both types are manageable with the correct advice and medication.
There are articles below that explore the condition in many different ways. Covering new research and evidence.
The University of Würzburg has shed light on the intricate mechanisms of insulin production in fruit flies, revealing surprising parallels with human physiology. This study offers crucial insights into how insulin-producing cells respond to metabolic changes, with potential implications for understanding and treating diabetes.
A new medical education programme for diabetes healthcare providers in the UK is focusing on upskilling the knowledge and training of diabetes management technologies & devices.
Cecilia Van Cauwenberghe from Frost & Sullivan’s TechCasting Group, explains how the COVID-19 pandemic is the scenario for testing and demonstrating the successful implementation of diabetes telehealth platforms.
Here, a leading clinical negligence specialist warns the UK may be heading for a “perfect storm” of diabetes complications, due to delayed COVID-19 referrals.
New research by the American Heart Association finds that obesity is a factor in almost half of all new cases, with obese individuals significantly more likely to get Type 2 diabetes.
Here, Mark Clements, MD PhD, paediatric endocrinologist, clinical investigator, and chief medical officer at Glooko Inc. takes part in a Q&A regarding his perspectives on remote clinical trials and data management tools.
Jane C Khoury & Shelley R Ehrlich from Division of Biostatistics and Epidemiology, Cincinnati Children’s Hospital Medical Center, highlight the consequences of foetal development in a “sweet” uterus – including the short- and long-term transgenerational outcomes.
Jean Van Rampelbergh PhD, VP Clinical & Regulatory at Imcyse SA, introduces ImotopesTM a cutting-edge immunotherapy science with an excellent safety profile that could cure Type 1 diabetes or drastically change treatment options.
Claus Møldrup, DrugsDisclosed.com Founder and Former Professor in Social Pharmacy at the University of Copenhagen, turns the spotlight on diabetes and explores how to improve patient wellbeing and national health outcomes.
While diabetes has been declared as a signifier for infection complications, researchers now say that data suggests it is three times as likely these individuals have severe COVID or are hospitalised.
Katerina Kousoulaki, Christos Tsatsanis, Tone-Kari K. Østbye and Francisco J. Barba of the AQUABIOPRO-FIT project discuss the health benefits of dietary products made from fish side streams.
